Ultime notizie per Aptose Biosciences (NASDAQ:APTO) Azioni

Aptose Biosciences

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Aptose Biosciences Inc

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

Aptos - United States Dollar

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining by more than 350 points on Friday.
The Dow traded up 0.82% to 44,228.50 while the NASDAQ rose 0.14% to 18,998.27. The S&amp;P 500 also rose, gaining, 0.31% to 5,966.91.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.5% on Friday.
In trading on Friday, communication services shares fell by 0.6%.
Top Headline
Shares of Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell over 5% on Friday after the company reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.
The company reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35 per share. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares shot up 16% to $109.17 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Shares of Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) got a boost, surging 19% to $30.26 following upbeat earnings.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 45% to $16.00 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 55% to $6.11 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 43% to $0.1390 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 41% to $0.1164 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $71.16 while gold traded up 1.1% at $2,704.00.
Silver traded up 1.1% to $31.275 on Friday, while copper fell 0.8% to $4.0940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.12%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.46%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 gained 1.35%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a>

Earnings

News

Markets

Analyst Ratings

Trading Ideas

AMIX

APTO

CETX

ESTC

INTU

MATW

REPL

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining by more than 250 points on Friday.
The Dow traded up 0.59% to 44,128.84 while the NASDAQ rose 0.08% to 18,986.80. The S&amp;P 500 also rose, gaining, 0.28% to 5,965.15.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.5% on Friday.
In trading on Friday, communication services shares fell by 0.6%.
Top Headline
Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) reported better-than-expected third-quarter EPS results.
The company said it sees FY25 earnings of $6.10 to $6.17 per share
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares shot up 16% to $109.17 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Shares of Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) got a boost, surging 19% to $30.26 following upbeat earnings.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 45% to $16.00 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 55% to $6.11 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 43% to $0.1390 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 41% to $0.1164 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $71.16 while gold traded up 1.1% at $2,704.00.
Silver traded up 1.1% to $31.275 on Friday, while copper fell 0.8% to $4.0940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.12%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.46%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 gained 1.35%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

ROST

Crude Oil Gains Over 1%; Ross Stores Earnings Top Views

U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 300 points on Friday.
Following the market opening Friday, the Dow traded up 0.72% to 44,184.62 while the NASDAQ rose 0.07% to 18,985.33. The S&amp;P 500 also rose, gaining, 0.35% to 5,969.29.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1% on Friday.
In trading on Friday, communication services shares fell by 0.4%.
Top Headline
Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and raised its outlook for FY24 gross margin.
&nbsp;The company reported quarterly earnings of 54 cents per share, which beat the analyst consensus estimate of 40 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) shares shot up 76% to $1.95 after declining around 75% on Wednesday.</li>
<li>Shares of DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) got a boost, surging 77% to $0.8931.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 48% to $16.37 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 52% to $6.53 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 44% to $0.1374 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 42% to $0.1148 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $70.67 while gold traded up 0.9% at $2,697.70.
Silver traded up 1.2% to $31.33 on Thursday, while copper fell 0.8% to $4.0910.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.2%, Germany's DAX gained 0.9% and France's CAC 40 rose 0.7%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 gained 1.4%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

DEVS

Dow Jumps 300 Points; Gap Posts Upbeat Earnings

WIIM

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8 million public offering.

Offerings

Aptose Biosciences Prices $8M Public Offering Of 40M Shares And 20M Warrants At $0.20 Per Unit; Warrants Priced At $0.25 Per Share And Expire In Five Years, With Closing Expected On November 25, 2024

Shares of Elastic N.V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY25 guidance <a href="https://www.benzinga.com/quote/ESTC/news">above estimates</a>.
Elastic reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 38 cents per share. The company reported quarterly sales of $365.361 million which beat the analyst consensus estimate of $355.900 million.
Elastic shares jumped 29.1% to $121.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 67.1% to $0.9855 in pre-market trading after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 50.4% to $1.88 in pre-market trading after dipping 62% on Thursday.</li>
<li>Beneficient  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) gained 30.7% to $1.15 in pre-market trading after gaining around 7% on Thursday.</li>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) gained 25.4% to $1.38 in pre-market trading after declining around 75% on Wednesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 19.4% to $12.98 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) gained 14.9% to $25.33 in pre-market trading after reporting better-than-expected third-quarter results.</li>
<li>Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) gained 10.4% to $6.90 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) climbed 8.7% to $1.63 in pre-market trading.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) gained 7% to $153.01 in pre-market trading after the company reported better-than-expected third-quarter EPS results..</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares tumbled 41.8% to $10.64 in pre-market trading after the company announced the pricing of $12.1 million public offering.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) fell 33.3% to $9.01 in pre-market trading.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 27.2% to $0.1430 in pre-market trading after the company announced its board approved a 1-for-35 reverse stock split.</li>
<li>Procaps Group S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) declined 18.7% to $0.90 in pre-market trading as the company said it faced Nasdaq delisting threat due to Form 20-F filing delay.</li>
<li>Carter Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) shares fell 10.6% to $16.86 in pre-market trading.</li>
<li>Real Messenger Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMSG#NASDAQ">RMSG</a>) dipped 16.2% to $3.51 in pre-market trading after jumping over 10% on Thursday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) fell 13.9% to $0.21 in pre-market trading after dipping more than 10% on Thursday.</li>
<li>Envoy Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares dipped 12.7% to $1.92 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.3% to $146.50 in pre-market trading. Reddit's shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company's stake, reported Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell 5.7% to $639.95 in today's pre-market trading. Intuit reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

BENF

CARE

Envoy Medical, Inc. - Class A Common Stock

COCH

KAPA

KSCP

PROC

RDDT

RMSG

VRPX

XCUR

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $7 to $2.

Price Target

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $2

Aptose Biosciences Announced Initiation Of The TUSCANY Study, Tuspetinib In Combination Therapy With Azacitidine And Venetoclax As A Frontline Triplet Combination Therapy For Patients Newly Diagnosed With Acute Myeloid Leukemia

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(1.19) by 68.91 percent.

Earnings Beats

Aptose Biosciences Q3 2024 GAAP EPS $(0.37) Beats $(1.19) Estimate

General

Aptose shares are trading higher after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co.

Shares of Zhibao Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) rose sharply in today's pre-market trading after the company announced that it has won a tender to provide high-end medical third party administration services to the People&#8217;s<a href="https://www.benzinga.com/quote/ZBAO/news"> Insurance Company of China Limited.</a>
Zhibao Technology shares jumped 18.8% to $3.99 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) gained 129.4% to $0.7599 in pre-market trading. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) rose 48.1% to $0.6040 in today's pre-market trading after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 25.8% to $0.1549 in pre-market trading after declining over 5% on Friday.</li>
<li>Perfect Moment Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NYSE">PMNT</a>) gained 25.2% to $1.29 in pre-market trading.</li>
<li>Cyclacel Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 21.7% to $1.28 in pre-market trading.</li>
<li>Polar Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) gained 18.8% to $0.47 in the pre-market trading session. Polar Power, last month, posted a profit for the second quarter.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 13.2% to $1.97 in pre-market trading.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 11.5% to $6.01 in pre-market trading.</li>
<li>Autozi Internet Technology (Global) Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) gained 5% to $3.15 in pre-market trading amid post-IPO volatility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Bluejay Diagnostics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) fell 13.3% to $0.16 in pre-market trading after declining around 6% on Friday.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares fell 13.1% to $0.2338 in pre-market trading. Focus Universal shares jumped over 41% on Friday after the company in a Form4 filing disclosed that CEO Desheng Wang bought 302,100 shares of stock at an average price of $0.18 per share.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares declined 12.1% to $2.05 in pre-market trading.</li>
<li>Graphex Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#NYSE">GRFX</a>) fell 12% to $0.21 in pre-market trading after surging 13% on Friday.</li>
<li>ShiftPixy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) shares fell 11.8% to $1.04 in pre-market trading. ShiftPixy recently announced the pricing of $2.5 million offering.</li>
<li>Agape ATP Corporation  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined 11.4% to $2.26 in pre-market trading after jumping 60% on Friday.</li>
<li>Autonomix Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares fell 10.9% to $0.60 in pre-market trading after jumping 14% on Friday.</li>
<li>Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) fell 10% to $5.31 in today's pre-market trading after gaining over 25% on Friday.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares dipped 5.8% to $35.70 in pre-market trading. Vice President Kamala Harris has expressed her support for American ownership of United States Steel, amidst ongoing foreign acquisition attempts.</li>
<li>Diversified Energy Company PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) declined 5.6% to $11.54 in pre-market trading. Keybanc analyst Tim Rezvan, last week, initiated coverage on Diversified Energy with an Overweight rating and announced a price target of $18.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

Movers

ATPC

BJDX

CYCC

FCUV

GRFX

PIXY

PMNT

POLA

SHLS

SIFY

STAF

TOVX

ZBAO

Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) to report quarterly earnings at 28 cents per share on revenue of $372.52 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Hello Group shares fell 0.6% to $6.60 in after-hours trading.</li>
<li>Analysts expect Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) to post quarterly earnings at 69 cents per share on revenue of $567.93 million. The company will release earnings after the markets close. Zscaler shares gained 0.1% to $200.00 in after-hours trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares rose in Friday's after-hours trading after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Aptose shares jumped 69.3% to $0.6874 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is projected to post quarterly earnings at 70 cents per share on revenue of $284.87 million. HealthEquity shares fell 0.6% to $79.10 in the after-hours trading session.</li>
<li>Analysts expect Sportsman&#8217;s Warehouse Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) to report a quarterly loss at 9 cents per share on revenue of $285.03 million after the closing bell. Sportsman&#8217;s Warehouse shares fell 1% to $2.08 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">Top 2 Real Estate Stocks That Could Blast Off This Quarter</a></li>
</ul>
Image generated using AI tools

MOMO

SPWH

Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/APS#TSX">APS</a>), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Ltd. ("Hanmi"). The loan is convertible as prepayment of milestone obligations under the Future Collaboration Agreement (as defined hereinafter) or repayable after the expected completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients. Aptose will use the proceeds from such loan for the development of tuspetinib. &nbsp;
Beyond the $10 million Facility Agreement, Aptose and Hanmi have agreed to negotiate a new tuspetinib co-development collaboration agreement (the "Future Collaboration Agreement'), intended to provide additional funding to accelerate clinical development of tuspetinib. Aptose licensed tuspetinib from Hanmi Pharmaceutical in November 2021.

Contracts

TSX:APS

Aptose Biosciences Secures $10M Loan From Hanmi Pharmaceutical For Tuspetinib Development; Companies To Negotiate New Co-Development Agreement For AML Treatment

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.86) by 50 percent.

Aptose Biosciences Q2 2024 GAAP EPS $(0.43) Beats $(0.86) Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $7 Price Target

<ul>
<li>TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML</li>
</ul>
<ul>
<li>TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML</li>
</ul>
<ul>
<li>TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study</li>
</ul>
<ul>
<li>TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated</li>
</ul>

Aptose Showcases Clinical And Preclinical Results For Tuspetinib (TUS) At The 2024 EHA Hybrid Congress

<a href="https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock" title="https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock">https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock</a>

Rumors

Aptose Biosciences Shares Move Higher; Traders Circulate Zacks Article Titled "Aptose Biosciences Upgraded to Buy: What Does It Mean for the Stock?"

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/APS#TSX">APS</a>), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share (or per common share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Aptose has agreed to issue unregistered series A warrants to purchase up to 3,855,000 common shares and series B warrants to purchase up to 3,855,000 common shares, each at an exercise price of $1.15 per share. The unregistered warrants will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares issuable upon exercise of the warrants. The series A warrants will expire five years from the date of shareholder approval and the series B warrants will expire eighteen months from the date of shareholder approval. The offering is expected to close on or about June 3, 2024, subject to the satisfaction of customary closing conditions. &nbsp;
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Aptose Announces $4.43M Registered Direct Offering Of 3.855M Shares Of Common Stock At A Price Of $1.15/Share, Priced At-the-Market Under Nasdaq Rules

Canaccord Genuity analyst John Newman maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $15 to $6.

Canaccord Genuity Maintains Buy on Aptose Biosciences, Lowers Price Target to $6

Warning: APTO is at high risk of performing badly

Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences is advancing the development of its promising drug tuspetinib as part of a ...

Aptose Biosciences Advances AML Triplet Therapy

Aptose Biosciences GAAP EPS of -$0.37 beats by $0.27

Aptose Biosciences ( ($APTO) ) has released its Q3 earnings. Here is a breakdown of the information Aptose Biosciences presented to its investors. ...

Aptose Biosciences Reports Q3 2024 Financial Highlights

Aptose Biosciences (APTO) announced initiation of the TUSCANY study, tuspetinib, TUS, in combination therapy with azacitidine, AZA, and venetoclax,...

Aptose Biosciences initiates TUSCANY Phase 1/2 study

H.C. Wainwright lowered the firm's price target on Aptose Biosciences (APTO) to $2 from $7 and keeps a Buy rating on the shares. The firm expects s...

Aptose Biosciences price target lowered to $2 from $7 at H.C. Wainwright

Aptose Biosciences (APTO) announced the pricing of its "reasonable best efforts" public offering with participation from the CEO and existing and n...

Aptose Biosciences to sell 40M shares at 20c in public offering

An update from Aptose Biosciences ( ($TSE:APS) ) is now available. Aptose Biosciences Inc., a clinical-stage oncology company, has announced an $8 ...

Aptose Biosciences Announces $8 Million Public Offering

Press Releases

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Biotech

NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

Aptose Reports Results for the Second Quarter 2024

Aptose Announces Adjournment of its Special Meeting of Shareholders

Financing

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Announces Results from Special Meeting of Shareholders

Aptose Reports Results for the Third Quarter 2024

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

HC Wainwright & Co.

Canaccord Genuity

Piper Sandler

RBC Capital

Cantor Fitzgerald

Comments

Aptose Biosciences

Notizie

Ultime notizie per Aptose Biosciences (NASDAQ:APTO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO